# CURIS INC (CRIS) · Edgar & Edgarette company card

> Curis (CRIS) saw revenue fall 13.4% in FY2025 to $9 million, operating margin -60.5% against a -15.8% median for biological products, (no diagnostic substances), equity 27.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1108205 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/CRIS) · [JSON](https://www.pops4.com/boards/company/CRIS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $9M |
| Revenue growth, 1 year | -13.4% |
| Revenue growth per year | -3.0% |
| Operating margin | -60.5% (prior year -408.3%) |
| Net margin | -80.3% |
| Operating cash flow | −$27M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $5M |
| Long-term debt | — |
| Total assets | $20M |
| Total equity | $5M |
| Equity ÷ assets | 27.4% |
| Return on equity | -138.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -207.55 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -60.5% in FY2025; revenue is hard to predict: its 80% range is ±36%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $9.4M (FY2025). Experience: revenue down 13.4% on the year, down 3.0% a year over 4 years; operating margin -60.5%, up from -408.3%. Soundness: equity 27.4% of assets, return on equity -138.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $5.8M and $12.5M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $5.5M to $13.2M. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -60.5% against a -15.8% median; growth -13.4% against 21.4%.

Range logged 2026-10-20, receipt 4c49dd6cdbd561c3, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 4, latest 2026-11-06 ([filing](https://www.sec.gov/Archives/edgar/data/1108205/000110465926123906/0001104659-26-123906-index.htm))
- Item 5.02 Director or officer change: 1, latest 2026-03-17 ([filing](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000016/0001108205-26-000016-index.htm))

## Recent filings

- 10-Q · filed 2026-11-13 · [filing](https://www.sec.gov/Archives/edgar/data/1108205/000110465926127050/0001104659-26-127050-index.htm)
- 8-K · filed 2026-11-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1108205/000110465926127041/0001104659-26-127041-index.htm)
- 8-K · filed 2026-11-06 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1108205/000110465926123906/0001104659-26-123906-index.htm)
- DEF 14A · filed 2026-11-02 · [filing](https://www.sec.gov/Archives/edgar/data/1108205/000114036126041419/0001140361-26-041419-index.htm)
- 8-K · filed 2026-10-19 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1108205/000110465926116910/0001104659-26-116910-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000118/0001108205-26-000118-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001108205.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1108205

## Cite

POPS4, Edgar & Edgarette: CURIS INC (CRIS) company card, from the company's own SEC filings, accessed 2026-11-21, https://www.pops4.com/boards/company/CRIS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

